Effects of therapy with [177Lu-DOTA0,Tyr 3]octreotate on endocrine function by Teunissen, J.J.M. (Jaap) et al.
ORIGINAL ARTICLE
Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate
on endocrine function
Jaap J. M. Teunissen & Eric P. Krenning & Frank H. de Jong & Yolanda B. de Rijke &
Richard A. Feelders & Maarten O. van Aken & Wouter W. de Herder &
Dik J. Kwekkeboom
Received: 6 July 2008 /Accepted: 17 April 2009 /Published online: 27 May 2009
# The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract
Purpose Peptide receptor radionuclide therapy (PRRT) with
radiolabelled somatostatin analogues is a novel therapy for
patients with somatostatin receptor-positive tumours. We
determined the effects of PRRT with [177Lu-DOTA0,Tyr3]
octreotate (177Lu-octreotate) on glucose homeostasis and the
pituitary-gonadal, pituitary-thyroid and pituitary-adrenal axes.
Methods Hormone levels were measured and adrenal
function assessed at baseline and up to 24 months of
follow-up.
Results In 35 men, mean serum inhibin B levels were
decreased at 3 months post-therapy (205±16 to 25±4 ng/l,
p<0.05) and follicle-stimulating hormone (FSH) levels
increased (5.9±0.5 to 22.7±1.4 IU/l, p<0.05). These levels
returned to near baseline levels. Total testosterone and sex
hormone binding globulin (SHBG) levels decreased (15.0±
0.9 to 10.6±1.0 nmol/l, p<0.05 and 61.8±8.7 to 33.2±
3.7 nmol, p<0.05), respectively, whereas non-SHBG-bound
T did not change. An increase (5.2±0.6 to 7.7±0.7 IU/l,
p<0.05) of luteinizing hormone (LH) levels was found at
3 months of follow-up returning to baseline levels thereafter.
In 21 postmenopausal women, a decrease in levels of FSH
(74.4±5.6 to 62.4±7.7 IU/l, p<0.05) and LH (26.8±2.1 to
21.1±3.0 IU/l, p<0.05) was found. Of 66 patients, 2
developed persistent primary hypothyroidism. Free thyroxine
(FT4) levels decreased (17.7±0.4 to 15.6±0.6 pmol/l,
p<0.05), whereas thyroid-stimulating hormone (TSH) and
triiodothyronine (T3) levels did not change. Reverse triiodo-
thyronine (rT3) levels decreased (0.38±0.03 to 0.30±
0.01 nmol/l, p<0.05). Before and after therapy adrenocorti-
cotropic hormone (ACTH) stimulation tests showed an
adequate response of serum cortisol (>550 nmol/l, n=18).
Five patients developed elevated HbA1c levels (>6.5%).
Conclusion In men 177Lu-octreotate therapy induced tran-
sient inhibitory effects on spermatogenesis, but non-SHBG-
bound T levels remained unaffected. In the long term,
gonadotropin levels decreased significantly in postmeno-
pausal women. Only a few patients developed hypothy-
roidism or elevated levels of HbA1c. Therefore, PRRT with
177Lu-octreotate can be regarded as a safe treatment
modality with respect to short- and long-term endocrine
function.
Keywords Tumour targeting . Peptide . Somatostatin .
Therapy . Radiolabelled peptides . Antibodies .
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Introduction
Treatment with radiolabelled somatostatin analogues, or
peptide receptor radionuclide therapy (PRRT), is a novel
treatment modality in patients with metastasized or inoper-
able somatostatin receptor-positive tumours, e.g. carcinoid,
paraganglioma or gastrinoma. Recent reports on the
effectiveness of PRRT with the most frequently used
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radioligands [90Y-DOTA0,Tyr3]octreotide (90Y-octreotide)
or [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate) in
patients with gastropancreatic neuroendocrine tumours
described 20–30% partial remissions [1–3].
Reported short-term side effects of PRRT included mild
nausea, vomiting and abdominal pain, but occurred only in
a minority of patients [4]. Furthermore, severe side effects
such as renal insufficiency and the occurrence of myelodys-
plastic syndrome or leukemia were rare [4, 5]. So far, two
cases of myelodysplastic syndrome [5] and several cases of
radiation-induced renal failure [6–8] have been reported.
Therefore, the bone marrow and kidneys remain the dose-
limiting organs with each patient receiving amino acid co-
infusion during treatment to reduce the renal radiation dose
and thereby the risk of renal failure [9].
Since many endocrine organs, such as the anterior
pituitary gland, endocrine pancreas, adrenal medulla and
thyroid, express somatostatin receptors (SSTRs), especially
the SSTR subtype 2, these organs are also potentially
targeted by PRRT [10–13]. Therefore, it is not unlikely that
patients treated with PRRT are at risk of developing
hormone disturbances or deficiencies during their follow-
up period. Until recently, however, limited data regarding
the effects of PRRT on endocrine function were available.
In a previous report on the therapeutic effect of 177Lu-
octreotate in a large group of patients with gastroenter-
opancreatic neuroendocrine tumours, we briefly reported on
the short-term effects of PRRT on endocrine function [5].
Therefore, the objective of the present study was to assess
both the short- and long-term effects of PRRT on the
functions of the anterior pituitary, gonads, thyroid, endo-
crine pancreas and adrenal glands.
Materials and methods
Patients and study design
Seventy-nine patients who were treated with 600−800 mCi
177Lu-octreotate (three to four cycles with 6- to 9-week
interval) between January 2000 and December 2004 and
with a follow-up period of 12−24 months were selected for
analysis. Only local (Dutch) residents were analysed,
because these had their follow-up at our institution. All
patients had tumour uptake on SSTR scintigraphy that was
at least as high as the physiological uptake in normal liver
tissue on planar imaging preceding therapy. Hormone
measurements were performed before each administration
of 177Lu-octreotate and at each follow-up visit.
Inclusion criteria were: Karnofsky performance score≥50,
creatinine clearance≥40 ml/min, haemoglobin>9.7 g/dl,
platelet count>75×109/l and WBC>2.0×109/l. All patients
gave written informed consent before inclusion in the study,
which was approved by the Medical Ethics Committee of the
hospital. 177Lu-octreotate preparation and administration of
therapy were performed as described earlier [5].
Hormone measurements
Blood samples were processed within 2 h after withdrawal.
Serum was stored at −20°C until assayed.
Gonadotropins, gonadal hormones and cortisol
Serum levels of luteinizing hormone (LH), follicle-stimulating
hormone (FSH), sex hormone binding globulin (SHBG) and
cortisol were measured using luminescence-based immuno-
metric or immunoassays (Immulite 2000, Diagnostic Products
Corp., Los Angeles, CA, USA). Serum estradiol (E2) and total
testosterone (TT) levels were measured using a no-extraction
coated tube radioimmunoassay (RIA) (Coat-a-Count, Diag-
nostic Products Corp., Los Angeles, CA, USA). Sensitivities
of the assays were 0.1 IU/l for FSH and LH, 0.1 nmol/l for
SHBG, 28 nmol/l for cortisol, 10 pmol/l for E2 and 0.1 nmol/
l for TT. Interassay coefficients of variation for LH and FSH
were<7%, for SHBG<5%, for cortisol<5%, for E2<10% and
for TT<9%. Non-SHBG-bound T levels were calculated by
using the mass action equation as described by Södergård et
al. [14]. The affinity constants used for the binding of
testosterone to SHBG and albumin were 5.97×108 l/mol
and 4.06×104 l/mol, respectively. Dimeric inhibin B levels
were assessed using an immunoenzymometric assay (Oxford
BioInnovation, Oxford, UK), The detection limit of the assay
was 10 ng/l. Interassay coefficients of variation were <15%
and<21% at concentrations of 215 and 19 ng/l, respectively.
Thyroid hormones
Serum free thyroxine (FT4) and triiodothyronine (T3) were
measured by chemiluminescence assays (Vitros ECi Immu-
nodiagnostic System, Ortho-Clinical-Diagnostics Inc.,
Rochester, NY, USA). Serum levels of thyroid-stimulating
hormone (TSH) were measured using the Immulite 2000
system. Reverse T3 (rT3) was measured by RIA as previously
described [15]. Interassay coefficients of variation amounted
to 4% for TSH, 5% for FT4, 3.3% for T3 and 10% for rT3.
HbA1c
Glycated haemoglobin, measured as HbA1c, was obtained
with the use of the HPLC method (Menarini 8160,
Menarini Diagnostics, Valkenswaard, The Netherlands).
The running between-day coefficient of variation was 1%
for both control levels (5.8 and 10.9%) [16].
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Hypothalamic-pituitary-adrenal (HPA) axis assessment
The 1 μg (low-dose) adrenocorticotropic hormone (ACTH)
stimulation test (LDST) was used to test the integrity of the
HPA axis. The LDST was performed in 39 patients before
therapy. Eighteen patients also had an LDST 12–18 months
after therapy. Cortisol was measured 0, 20, 30 and 60 min
after the injection of 1 µg tetracosactrin (Synacthen,
Novartis Pharma) intravenously.
The solution of 1 µg ACTH/ml was used immediately
after preparation. The intravenous line used was flushed
with saline after the administration and after each time a
blood sample was taken. A stimulated peak cortisol
concentration of at least 550 nmol/l was considered to be
an adequate response.
Statistical analyses
All results are expressed as mean concentrations ± standard
error of the mean (SEM). Hormone levels were analysed
using repeated measures analysis of variance (ANOVA)
with Bonferroni correction for multiple comparisons. For
the HPA axis analysis a paired Student’s t test was used;
p values <0.05 (two-tailed) were considered significant.
Results
The patients’ characteristics are listed in Table 1. Data from
35 men were available for analysis. Three were excluded at
baseline: one had severe chemotherapy-induced hypogonad-
ism, one had testicular atrophy and one had high levels of
FSH and LH suggestive of a co-existing gonadotropin-
secreting pituitary adenoma, which was not further analysed.
At baseline, one patient had combined low TT
(<8.1 nmol/l) and inhibin B (<150 ng/l) levels, two patients
had isolated low TT levels, two other patients had low non-
SHBG-bound T (<5.9 nmol/l) and another ten patients had
isolated low inhibin B levels.
No. of patients Mean (range) %
Total 79
Gender
Male 38 48
Age 58.4 (30–83)
Female 41 52
Age 54.8 (20–74)
Weight (kg) 74.3 (43–142)
BMI (kg/m2) 25.0 (15.6–45.1)
Height (cm) 172 (152–196)
Karnofsky Performance Score 89.4 (50–100)
Diagnosis
Carcinoid 49 62
NET of unknown origin 8 10
NET pancreas 15 20
Gastrinoma 1 1
Insulinoma 1 1
Hürthle cell thyroid carcinoma 3 4
Medullary thyroid carcinoma 1 1
Paraganglioma 1 1
Metastases
Liver 66 84
Bone 18 23
Prior therapy
Surgery 36 46
Chemotherapy 6 8
External beam radiotherapy 3 4
Somatostatin analogue therapy 36 46
Table 1 Baseline patient
characteristics
BMI body mass index, NET
neuroendocrine tumour
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The mean inhibin B level decreased significantly from
205±16 ng/l to a nadir level of 25±4 ng/l at 3 months after
177Lu-octreotate therapy (p<0.05) and returned to near pre-
treatment levels in the follow-up period thereafter. At
24 months post-therapy, although marginal, the inhibin B
level was still significantly decreased (Fig. 1a). Mean FSH
levels had a mirrored course with a transient increase from
5.9±0.5 IU/l to a maximum of 22.7±1.4 IU/l 3 months after
the last therapy. Twenty-four months after the last therapy,
the mean FSH level was not significantly different from
baseline. The mean TT level decreased significantly from
15.0±0.9 nmol/l at baseline to 12.3±0.7 nmol/l at 3 months
(p<0.05) with a further decline to 10.6±1.0 nmol/l at
24 months after therapy (Fig. 1b). The mean LH level
increased from 5.2±0.6 IU/l to 7.7±0.7 IU/l at 3 months of
follow-up (p<0.05) and returned to levels not significantly
different from baseline at 6 months.
Concomitant with the decrease of TT, the mean SHBG
level decreased significantly from a baseline level of 61.8±
8.7 nmol/l to a nadir of 33.2±3.7 nmol/l at 24 months after
the last therapy (p<0.05). The calculated levels of non-
SHBG-bound T did not change significantly (Fig. 1c).
Based on the levels of FSH, LH, inhibin B and E2, and
age before therapy, three groups of women (41 patients in
total) could be distinguished. Eight women had hormonal
changes during follow-up which were suggestive of
menopausal transition and were therefore excluded. Since
no menstrual data were available from six premenopausal
women, these women were also excluded from analysis.
Gonadotropin analysis was performed in 21 postmeno-
pausal women. Five women were excluded because of
hormonal changes due to concomitant disease (n=3),
previous cranial external beam radiation because of
meningeoma (n=1) and temporary use of high-dose opioid
medication (n=1). One 39-year-old woman was excluded
because of bilateral oophorectomy, followed by hormone
replacement therapy.
In the postmenopausal women, both mean inhibin B and E2
were at low levels, <10 ng/l and <50 pmol/l, respectively, at
baseline and did not change significantly thereafter. Before
therapy, the mean FSH concentration was 74.4±5.6 IU/l.
During follow-up it decreased significantly to 62.4±7.7 IU/l at
24 months of follow-up. The mean LH concentration, which
was 26.8±2.1 IU/l before therapy, decreased significantly to
21.1±3.0 IU/l at 24 months (p<0.05). (Fig. 2).
Sixty-six patients were included for analysis of thyroid
hormone status. Excluded were ten patients with thyroid-
associated conditions before therapy including primary
hypothyroidism (n=4), TSH suppressive therapy for thyroid
carcinoma (n=4), hyperthyroidism (n=1) and combined
neck surgery and external beam radiotherapy (n=1). Fur-
thermore, three patients were excluded because they had
either undetected hypothyroidism (n=1) or subclinical
hypothyroidism (n=2) before 177Lu-octreotate therapy and
were subsequently started on thyroxine therapy. After the
third cycle of therapy one patient developed anti-TPO
antibody-positive hypothyroidism. Another patient gradually
Fig. 1 a, b Longitudinal analyses of mean (± SEM) serum levels of
FSH (dotted line with open squares), inhibin B (black line with open
circles), LH (dotted line with filled squares) and TT (black line with
filled circles) in 35 men with SSTR-positive tumours before, during and
up to 24 months after 600–800 mCi 177Lu-octreotate therapy. Bars
along both y-axes represent the reference range (4 SD) values, *p<0.05.
c Longitudinal analyses of mean (± SEM) serum levels of TT (black
line with filled circles), SHBG (black line with filled triangles) and non-
SHBG-bound testosterone (n-SHBG-bound T, black line with filled
diamonds) in 35 men with SSTR-positive tumours before, during and
up to 24 months after 600–800 mCi 177Lu-octreotate therapy. Bars
along both y-axes represent the reference range (4 SD) values, *p<0.05
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developed primary hypothyroidism after therapy and was
eventually started on substitution therapy 3.5 years after
177Lu-octreotate therapy. Thyroid hormone levels from these
patients were included in the analyses until hypothyroidism
was evident.
The course of the mean thyroid hormone levels of the
included patients is shown in Fig. 3. The mean FT4
decreased significantly from 17.7±0.4 to 15.6±0.6 pmol/l
(reference range: 11−25 pmol/l, p<0.05); TSH and T3 levels
did not change significantly. The mean rT3 concentration of
0.38±0.03 nmol/l was above the reference range (0.14–
0.34 nmol/l) before therapy. During therapy a significant 18%
decrease of mean rT3 levels with a nadir of 0.30±0.01 nmol/
l after a cumulative dose of 400 mCi was found (p<0.05).
Thereafter the mean rT3 level increased slowly to 0.32±
0.03 nmol/l 24 months after therapy. The ratio of T3 over rT3
(T3/rT3), with a T3/rT3 of 6.24±0.03 at baseline, was
significantly elevated with a maximum of 7.54±0.33 after a
cumulative dose of 400 mCi (p<0.05) after which it returned to
levels not significantly different from baseline. In a subanalysis,
in which three groups of patients were analysed according to
their outcome of tumour assessment at 3 months of follow-up
(progressive disease, PD; stable disease, SD; minor or partial
remission, MR or PR) a significant decrease of mean rT3 level
during therapy (p<0.05) was demonstrated in the groups with
SD and MR or PR whereas in the PD group no significant
change was observed (Fig. 4).
An LDST was performed before therapy in 39 patients,
which showed stimulated cortisol values higher than the cut-
off value of 550 nmol/l in all patients. The mean peak level
after the LDST was 822±28 nmol/l. The LDST was repeated
12–18 months after the last therapy in 18 patients (8 men, 10
women). All patients again had stimulated cortisol values
higher than 550 nmol/l after 177Lu-octreotate therapy. The
mean peak cortisol response before therapy was significantly
higher than after therapy in these patients (909±57 nmol/l vs
822±35 nmol/l, p<0.001, n=18) (Fig. 5).
Of 79 patients, 9 had diabetes mellitus diagnosed before
treatment and were either on subcutaneous insulin therapy
(n=4) or oral anti-glycaemic agents (n=5). Furthermore,
one patient had an insulinoma and another patient had an
abnormal haemoglobin pattern and therefore the serum was
Fig. 3 Longitudinal analysis of mean (± SEM) serum levels of TSH
(dotted line with filled triangles), FT4 (black line with filled circles),
T3 (black line with filled diamonds), rT3 (dotted line with open
triangles) and T3/ rT3 ratio (line with open circles) of 66 patients with
SSTR-positive tumours before, during and up to 24 months after 600–
800 mCi 177Lu-octreotate therapy. Bars along both y-axes represent
the reference range (4 SD) values, *p<0.05
Fig. 2 Longitudinal analysis of mean (± SEM) serum levels of FSH
(dotted line with open squares) and LH (dotted line with filled
squares) in 21 postmenopausal women with SSTR-positive tumours
before, during and up to 24 months after 600–800 mCi 177Lu-
octreotate therapy. The mean inhibin B and E2 levels are not shown as
these were at normal low postmenopausal levels (<10 ng/l and<
50 pmol/l, respectively). Bars along both y-axes represent the
reference range (4 SD) values, *p<0.05
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unfit for HbA1c measurement. Five patients had elevated
HbA1c (>6.5%) before
177Lu-octreotate therapy three of
whom were started on oral anti-glycaemic drugs during or
after 177Lu-octreotate therapy. Six patients developed high
levels of HbA1c after PRRT. In one patient this occurred
after pancreatic surgery. In the other five patients, elevated
HbA1c levels occurred after 2–30 months from study
inclusion (Table 2). Analysis in 69 patients demonstrated
a decrease of HbA1c from 5.7±0.1 to 5.5±0.1% (p<0.05)
during therapy, but an increase to 6.0±0.1% (p<0.05)
thereafter.
Discussion
Besides the currently known complications and adverse
effects due to the non-specific radiation absorbed dose to
the bone marrow and kidneys, specific receptor-related
effects on non-tumourous tissue by PRRT have not been
studied in detail. SSTRs are expressed in most hormone-
secreting organs, such as pituitary gland, pancreas, thyroid
and adrenals, as evidenced by in vitro studies as well as by
the physiological uptake in vivo during somatostatin
receptor scintigraphy [10, 17–20]. Although the receptor
density of SSTRs in normal, non-pathological hormone-
secreting organs is not as high as observed in neuroendocrine
tumours, the presence of SSTRs implicates the possibility of
specific receptor-mediated targeting by radiolabelled somato-
statin analogues. Furthermore, as the radiopharmaceuticals
used in PRRT are systemically administered, all organs will
receive an additional non-specific dose, including those
organs that are known to be radiosensitive (e.g. the gonads).
Of our 35 male patients, 15 (43%) had evidence of
hypogonadism prior to PRRT. Gonadal dysfunction in
patients with disseminated cancer prior to chemotherapeutic
treatment has been reported by Chlebowski et al. [21]. A
relationship between markedly decreased gonadal function
and weight loss was also observed. Furthermore, other
factors, including age, history of alcohol intake and liver
disease, have been reported to have effects on the TT levels
in male patients [22]. As there are many factors that may
cause decreased TT levels, a specific or common cause of
the high percentage of hypogonadism within our group of
patients before PRRT is difficult to point out. Because
of the very similar patterns of hormonal changes observed
after PRRT in men with normal or low levels of TT before
therapy (data not shown), it is likely that these additional
factors did not contribute to the observed change in
hormone levels in our study.
The decrease of mean TT level coincided with a
decrease of SHBG level, whereas the mean non-SHBG-
bound T remained stable after PRRT. These observations
Fig. 5 Mean peak cortisol responses with the low-dose (1 μg) ACTH
stimulation test in 18 patients before and 12–18 months after 177Lu-
octreotate therapy are shown. Each dotted line connects one individual
patient
Table 2 Number of patients who were evaluable for HbA1c
percentages based on their HbA1c % at baseline and after PRRT.
Patients excluded at baseline were medically treated patients with
diabetes (n=9), one patient who had an insulinoma and one patient
who had with an abnormal haemoglobin pattern
Post-therapy
HbA1c (in %) >6.5 e6.5 Total
Baseline >6.5 5 (100%) 0 (0%) 5
≤6.5 6* (10%) 57* (90%) 63
Total 11 57 68
*One patient developed elevated levels of HbA1c after Whipple
surgery
Fig. 4 Longitudinal analysis of mean (± SEM) serum levels of rT3 in
patients with SSTR-positive tumours before, during and at 3 months
of follow-up after 600–800 mCi 177Lu-octreotate therapy grouped
according to their therapy outcome (minor remission and partial
remission, MR & PR, filled circles; stable disease, SD, filled
diamonds; progressive disease, PD, filled triangles) at 3 months of
follow-up. Bars along the y-axis represent the reference range values,
*p<0.05
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are in line with findings of de Ronde et al. [23] who
demonstrated a strong positive relationship between SHBG
and TT levels and no or only a weak positive association
between SHBG and circulating non-SHBG-bound T levels.
Because SHBG correlates negatively with body mass index
(BMI) [24], a possible explanation for the decrease of
SHBG is the significant increase of BMI in our patients
from 24.0±0.7 kg m-2 to a maximum of 25.3±0.8 kg m-2 at
12 months of follow-up. Furthermore, we found a weak
positive, but significant correlation (Spearman’s rho=0.29,
p=0.01) between FT4 and SHBG (data not shown). A
correlation between FT4 and SHBG was demonstrated
during thyroid hormone replacement therapy in hypothyroid
men by Cavaliere et al. [25]. However, whether the relatively
small increase of mean BMI or the limited decline in mean
FT4 level observed in our study is responsible for the marked
decline of SHBG is questionable. In theory, impaired liver
function after therapy can also cause decreased SHBG
levels. This is unlikely, however, because of unchanged
albumin levels and stable or decreased serum levels of γ-GT,
alkaline phosphatase, aspartate aminotransferase and alanine
aminotransferase throughout the whole study period (data
not shown).
Our data indicate that transient impairment of spermato-
genesis occurs following PRRT. A significant decrease of
mean serum inhibin B levels with a concomitant increase in
FSH levels was observed, with recovery to almost pre-
treatment levels after 24 months. This is in line with several
studies in patients with differentiated thyroid carcinoma who
received radioiodine therapy [26–29]. Inhibin B is produced
in the Sertoli cells of the testis and is the major feedback
regulator of FSH [30, 31]. It has been demonstrated that
serum inhibin B levels are positively correlated with
spermatogenic status and sperm count [32, 33]. Therefore,
although we did not perform semen analyses, our results
likely indicate temporarily impaired spermatogenesis.
Both the gonadal and pituitary gland function are
potentially at risk after PRRT. Effects on gonadotroph
levels after 177Lu-octreotate therapy was demonstrated in
postmenopausal women. A significant decrease in both
FSH and LH was found. The observed decrease in mean
FSH and LH level of approximately 12.5 and 8.2% per
year, respectively, was higher than could be expected
because of ageing as such. In a study of 680 postmeno-
pausal women, the decrease of gonadotropin levels between
the ages of 55 and 75 years was less than 1% per year [34].
Of 66 patients, 2 (3%) developed primary hypothyroidism
after treatment. One patient had hypothyroidism with the
development of anti-TPO antibodies suggesting autoimmune-
induced hypothyroidism. The other patient had slowly
progressive primary hypothyroidism and was put on substi-
tution therapy 3.5 years after 177Lu-octreotate therapy.
Thyroid hormone analyses of the total group demonstrated
a significant decrease of FT4 at the end of the study period.
This is in line with the significant decrease of FT4 levels we
reported earlier [5]. The decline of FT4 was not accompanied
by a significant increase of TSH or T3, though trends
towards an increase and decrease, respectively, were noticed.
Of interest, analysis excluding the two hypothyroid patients
revealed no significant change in FT4, TSH or T3. Since
chronicity and severity of disease might have an impact on
the thyroid hormone status and even can induce non-
thyroidal illness (NTI), the observed changes of thyroid
hormones in the long term could reflect the development of
NTI rather than the effect of PRRT. Signs of NTI were
observed at baseline with an increased mean level of rT3.
Specific changes in thyroid hormone levels were reported to
correlate with the severity of illness or even to be prognostic
for survival in critically ill patients [35]. Directly after the
first cycle of PRRT, rT3 returned to reference range values.
Thereafter, rT3 slowly increased but remained within the
normal reference range. The active over inactive thyroid
hormone (T3/rT3) ratio had a similar, but inverse pattern.
These changes suggest a rapid change to a more favourable
disease state directly after initiation of PRRT, which persists
during follow-up. A subanalysis of patients according to
therapy outcome indicated that patients who had PD had a
non-significant change in rT3 level, whereas the other
patients had a significant decrease, returning to the normal
range during therapy. Therefore, in our group of patients, the
change in rT3 and T3/rT3 ratio probably reflected changes in
the disease status.
The HPA axis is not affected by PRRT in terms of intact
adrenal reserve. All patients had adequate responses with
the LDST before therapy. Additionally, adequate responses
in 18 patients after therapy indicated no apparent primary or
secondary adrenal insufficiency. In a recent meta-analysis
on the diagnosis of adrenal insufficiency, it was concluded
that a cut-off value between 500 and 600 nmol/l cortisol is
necessary to achieve reasonable sensitivity for the detection
of both primary and secondary adrenal insufficiency [36].
Furthermore, the LDST is a valid replacement for the
commonly used short Synacthen test and the insulin
tolerance test (ITT), of which the latter is widely regarded
as the gold standard test for the integrity of the HPA axis
[37]. Unfortunately, the ITT is not completely safe and is
costly and difficult to perform in an outpatient setting, thus
hampering its clinical use.
Interestingly, the mean peak cortisol level after PRRT
was significantly lower than before therapy. Whether this
subtle difference in LDST response after therapy reflects
radiation-induced partial adrenal insufficiency or simply a
less stressful state of the patients is not clear. However,
Schmiegelow et al. reported similar findings in 73 patients
treated with radiotherapy and chemotherapy for childhood
brain tumours with a mean follow-up of 15 years [38].
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Nineteen percent of the patients had insufficiency of the
HPA axis, whereas the remainder of patients, even though
with an adequate response to an ACTH test or ITT, had
lower peak cortisol levels compared with controls. The
external beam radiotherapy, not chemotherapy, was
regarded as the main factor that had contributed to the
observed adrenal insufficiency. It was concluded that this
group might be potentially at risk of becoming HPA axis
insufficient in the future. Lifelong follow-up was recom-
mended in these patients. Although it is difficult to compare
177Lu-octreotate therapy with external beam radiation
therapy in terms of dose tempo, exposure area and period
of follow-up, these studies indicate that despite the
adequate LDST responses found in our patients, awareness
of a radiation-induced disturbance of the HPA axis is
important in the long-term follow-up.
Of 62 patients, 5 (8%) developed increased levels of
HbA1c after
177Lu-octreotate therapy without any obvious
cause, such as subsequent pancreatic surgery. Pancreatic
islets express somatostatin receptors, especially the subtype
SSTR2a [39]. However, 46% of our patients used somato-
statin analogues, such as octreotide, during and/or after
therapy. Therefore, besides the possibility of a direct
radiation effect as the cause of the observed subtle, but
significant increase of mean HbA1c after therapy, long-term
treatment with somatostatin analogues could have contrib-
uted as well.
Summarizing, in men 177Lu-octreotate therapy induced
transient inhibitory effects on spermatogenesis, but non-
SHBG-bound T levels remained unaffected. In the long
term, gonadotropin levels decreased significantly in post-
menopausal women. Only a small number of patients
developed hypothyroidism or elevated levels of HbA1c.
No clinically apparent relevant effect was observed on
pituitary-adrenal function. Despite temporary and minor
hormonal changes, PRRT with 177Lu-octreotate can be
regarded as a safe treatment modality with respect to the
short- and long-term endocrine function.
We conclude that patients who are treated with 177Lu-
octreotate therapy may develop radiation-induced hormone
disturbances, some of which have been proven to be
temporary and which are in general mild. No severe
hormone imbalance was observed and, therefore, 177Lu-
octreotate therapy, in terms of endocrine sequelae, can be
regarded as safe. However, awareness of the possibility of
changes in, and thereby surveillance of, the endocrine status,
is important and implicates the necessity of future studies.
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